文献速递骨软组织肉瘤与黑色素瘤

儿童非横纹肌肉瘤软组织肉瘤新药优先研究:COG报告

Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group.
PubMed 文献 · Eur J Cancer · 2025-07-06

儿童肿瘤协作组(COG)软组织肉瘤委员会成立非横纹肌肉瘤软组织肉瘤(NRSTS)新药工作组,建立评估框架并优先筛选药物。免疫检查点抑制剂和酪氨酸激酶抑制剂被确定为可纳入儿童NRSTS 2期或3期临床试验的候选药物类别,同时识别了其他类别药物的文献空白和实践障碍。

要点

  • COG建立NRSTS新药评估框架,优先筛选用于儿童NRSTS研究的新药。
  • 免疫检查点抑制剂和酪氨酸激酶抑制剂被选为2/3期试验候选类别。
  • 其他类别药物存在文献空白和实践障碍,需指导未来药物开发。

核心结论

  • 免疫检查点抑制剂和酪氨酸激酶抑制剂被COG软组织肉瘤委员会确定为儿童NRSTS 2期或3期临床试验的候选药物类别。

研究设计与样本

  • COG软组织肉瘤委员会成立NRSTS新药工作组,建立评估框架并优先筛选药物。
  • NRSTS包括70余种肿瘤,占儿童癌症约4%,转移或复发患者预后极差。

主要发现

  • 免疫检查点抑制剂和酪氨酸激酶抑制剂被确定为候选药物类别。
  • 其他类别药物存在文献空白和实践障碍,需指导未来药物开发。

临床怎么用

  • 可将免疫检查点抑制剂和酪氨酸激酶抑制剂优先纳入儿童NRSTS的2期或3期临床试验。

局限性

  • NRSTS组织学、分子和临床异质性大,且各类型罕见,研究挑战独特。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) is a group of over 70 tumors that occur across the age range and account for approximately 4 % of childhood cancers. Patients with metastatic or relapsed NRSTS have a dismal prognosis. The histologic, molecular, and clinical heterogeneity of NRSTS and the rarity of individual types pose unique challenges to the study of these diseases. The Children's Oncology Group (COG) Soft Tissue Sarcoma (STS) Committee established a NRSTS Novel Agents Working Group to identify and prioritize agents for further study in pediatric NRSTS, similar to recent efforts in Ewing sarcoma, rhabdomyosarcoma and osteosarcoma. We report the framework that was used to evaluate agents and the results of this evaluation. Immune checkpoint inhibitors and tyrosine kinase inhibitors were identified by the COG STS Committee as candidate classes of agents for inclusion in phase 2 or phase 3 clinical trials of pediatric NRSTS. Gaps in the existing literature and practical barriers were identified for additional classes of agents to guide future drug development efforts.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Crane JN, Douglass DP, Oberoi S, et al. Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur J Cancer. 2025. PMID: 40651390. doi:10.1016/j.ejca.2025.115600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。